Please use this identifier to cite or link to this item:
https://doi.org/10.1093/annonc/mdx419
DC Field | Value | |
---|---|---|
dc.title | Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer) | |
dc.contributor.author | Nokihara, H | |
dc.contributor.author | Lu, S | |
dc.contributor.author | Mok, TSK | |
dc.contributor.author | Nakagawa, K | |
dc.contributor.author | Yamamoto, N | |
dc.contributor.author | Shi, YK | |
dc.contributor.author | Zhang, L | |
dc.contributor.author | Soo, RA | |
dc.contributor.author | Yang, JC | |
dc.contributor.author | Sugawara, S | |
dc.contributor.author | Nishio, M | |
dc.contributor.author | Takahashi, T | |
dc.contributor.author | Goto, K | |
dc.contributor.author | Chang, J | |
dc.contributor.author | Maemondo, M | |
dc.contributor.author | Ichinose, Y | |
dc.contributor.author | Cheng, Y | |
dc.contributor.author | Lim, WT | |
dc.contributor.author | Morita, S | |
dc.contributor.author | Tamura, T | |
dc.date.accessioned | 2022-04-07T07:56:31Z | |
dc.date.available | 2022-04-07T07:56:31Z | |
dc.date.issued | 2017-11-01 | |
dc.identifier.citation | Nokihara, H, Lu, S, Mok, TSK, Nakagawa, K, Yamamoto, N, Shi, YK, Zhang, L, Soo, RA, Yang, JC, Sugawara, S, Nishio, M, Takahashi, T, Goto, K, Chang, J, Maemondo, M, Ichinose, Y, Cheng, Y, Lim, WT, Morita, S, Tamura, T (2017-11-01). Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). ANNALS OF ONCOLOGY 28 (11) : 2698-2706. ScholarBank@NUS Repository. https://doi.org/10.1093/annonc/mdx419 | |
dc.identifier.issn | 09237534 | |
dc.identifier.issn | 15698041 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/218598 | |
dc.description.abstract | Background: Chemotherapy remains a viable option for the management of advanced non-small-cell lung cancer (NSCLC) despite recent advances in molecular targeted therapy and immunotherapy. We evaluated the efficacy of oral 5-fluorouracilbased S-1 as second- or third-line therapy compared with standard docetaxel therapy in patients with advanced NSCLC. Patients and methods: Patients with advanced NSCLC previously treated with≥1 platinum-based therapy were randomized 1: 1 to docetaxel (60 mg/m2 in Japan, 75 mg/m2 at all other study sites; day 1 in a 3-week cycle) or S-1 (80-120 mg/day, depending on body surface area; days 1-28 in a 6-week cycle). The primary endpoint was overall survival. The non-inferiority margin was a hazard ratio (HR) of 1.2. Results: A total of 1154 patients (577 in each arm) were enrolled, with balanced patient characteristics between the two arms. Median overall survival was 12.75 and 12.52 months in the S-1 and docetaxel arms, respectively [HR 0.945; 95% confidence interval (CI) 0.833-1.073; P=0.3818]. The upper limit of 95% CI of HR fell below 1.2, confirming non-inferiority of S-1 to docetaxel. Difference in progression-free survival between treatments was not significant (HR 1.033; 95% CI 0.913-1.168; P=0.6080). Response rate was 8.3% and 9.9% in the S-1 and docetaxel arms, respectively. Significant improvement was observed in the EORTC QLQ-C30 global health status over time points in the S-1 arm. The most common adverse drug reactions were decreased appetite (50.4%), nausea (36.4%), and diarrhea (35.9%) in the S-1 arm, and neutropenia (54.8%), leukocytopenia (43.9%), and alopecia (46.6%) in the docetaxel arm. Conclusion: S-1 is equally as efficacious as docetaxel and offers a treatment option for patients with previously treated advanced NSCLC. | |
dc.language.iso | en | |
dc.publisher | OXFORD UNIV PRESS | |
dc.source | Elements | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Oncology | |
dc.subject | docetaxel | |
dc.subject | non-inferiority | |
dc.subject | previously treated NSCLC | |
dc.subject | S-1 | |
dc.subject | phase 3 study | |
dc.subject | PHASE-3 | |
dc.type | Article | |
dc.date.updated | 2022-04-07T02:37:57Z | |
dc.contributor.department | CANCER SCIENCE INSTITUTE OF SINGAPORE | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.1093/annonc/mdx419 | |
dc.description.sourcetitle | ANNALS OF ONCOLOGY | |
dc.description.volume | 28 | |
dc.description.issue | 11 | |
dc.description.page | 2698-2706 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with plat.pdf | 573.58 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.